BioCatch

We are a global technology company that has evolved far beyond our origins in photographic film. Today, we operate across healthcare, electronics, business innovation, and imaging, with over 70,000 employees worldwide working to deliver 'Value from Innovation.' Our healthcare segment spans diagnostic imaging, endoscopic imaging, medical systems, regenerative medicine, and life sciences - supporting everything from early disease detection to biopharmaceutical development and manufacturing. In biotechnology specifically, we operate contract development and manufacturing organization (CDMO) services, helping partners develop and produce vaccines, gene therapies, and other biologics. We bring deep expertise in lipid nanoparticles, liposomes, mRNA synthesis, and advanced manufacturing technologies. Our facilities in Denmark, the United States, and other global locations provide GMP manufacturing capabilities, while our commitment to sustainability includes powering sites with 100% renewable energy.

Founded in 1978, Biogen stands as one of the world's first global biotechnology companies, pioneering innovative science to deliver transformative medicines for patients facing devastating neurological diseases. Headquartered in Cambridge, Massachusetts with major manufacturing operations in North Carolina's Research Triangle Park, Biogen has spent nearly 50 years pushing the boundaries of what's possible in biotechnology. The company focuses on some of the most challenging disease areas including multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, lupus, and postpartum depression. Biogen's mission is rooted in deep scientific expertise and the courage to take bold risks. With close to 2,500 U.S. employees in research and development alone, plus over 1,500 manufacturing employees in North Carolina, Biogen leverages its understanding of human biology to advance first-in-class treatments and therapies. The company's culture - described as "Caring Deeply. Working Fearlessly. Changing Lives™" - reflects its unwavering commitment to patients, combining rigorous science with a profound sense of purpose to create value for shareholders and communities worldwide. Through continuous innovation in neurology, immunology, and rare diseases, Biogen aims to turn scientific breakthroughs into tangible hope for millions of patients.

Bioptimus has rapidly established itself as a leader in AI for biology, securing $76 million in funding to build the first universal AI foundation model for biology. Their flagship H-Optimus model ranks #1 out of 22 foundation models for digital pathology, with the company on track to reach 1 million downloads across its foundation models. Approximately 100 scientific publications annually leverage Bioptimus models to advance research, demonstrating significant academic adoption and impact. Training on an unprecedented 2 billion images and benefiting from data contributed by over 4,000 clinical practices, Bioptimus breaks down biological data silos to connect information from molecules to entire organisms. This comprehensive approach enables breakthrough discoveries in drug discovery, clinical trials, and patient treatment decisions. By transforming multiscale biological data into actionable insights, Bioptimus accelerates innovation in biomedicine and beyond, helping researchers and clinicians better understand complex biological systems.

Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research. The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.

In 2013, Formation Bio was founded with a clear mission: to bring new treatments to patients faster and more efficiently. The founders recognized a critical bottleneck in drug development - while biotech innovation and AI were generating new drug candidates at an unprecedented pace, the process of developing these drugs was becoming exponentially more expensive and time-consuming. This widening gap between scientific discovery and patient access needed to be bridged. Formation Bio began as TrialSpark, initially focused on building clinical trial technology tools and operating as a CRO before evolving to acquire and develop its own drug portfolio. In December 2023, the company rebranded to Formation Bio to reflect its expanded vision. Today, the company operates as an AI-native pharma company that acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms, developing them through a proprietary technology platform. By bringing together the best of tech and pharma - deep expertise in drug selection, drug development, and software engineering - Formation Bio optimizes all aspects of clinical drug development. The company integrates AI and data-driven approaches across the entire development lifecycle, from drug acquisition to NDA submission, enabling more efficient trial design, faster trial completion, and higher quality data capture.

We're translating the genetic language of the adaptive immune system into products that can diagnose and treat disease. When we started in 2009, my brother Harlan and I saw that if we could actually read how the immune system detects and fights illness, we could harness that natural power to help people. The adaptive immune system is incredibly sophisticated - it's identifying and addressing disease before you even feel sick. We've spent over a decade building our proprietary platform to decode these immune signals at scale. Today, we're applying what we've learned across three areas: life sciences research, clinical diagnostics, and drug discovery. Our clonoSEQ test helps doctors detect minimal residual disease in blood cancer patients with remarkable precision. And through our Immune Medicine Platform, we're using advances in computational biology and machine learning to turn vast systems of biology into actionable data. The goal is simple but ambitious: use the wisdom inside each person's immune system to transform how medicine detects and treats disease.